                  An Open-Label, Parallel, Randomized Study to Evaluate the Performance of Needle Placements for Diagnostic and Therapeutic Neuraxial Procedures, Using a Handheld Tactile Imaging-based Method Versus Palpation  [STUDY_ID_REMOVED]                 Document Type: Protocol  Document Date: November 25, 2020 
  An Open-Label, Parallel, Randomized Study to Evaluate the Performance of Needle Placements for Diagnostic and Therapeutic Neuraxial Procedures, Using a Handheld Tactile Imaging-based Method Versus Palpation Version 2 / 25 November 2020  Regulatory Sponsor:  IntuiTap Medical, Inc.  [ADDRESS_910667], Suite J  Houston, TX  [ZIP_CODE]     Jessica Traver  Chief Executive Officer  Phone: [PHONE_13984] Protocol Identifiers: INT-001 Study Type: Multi-center, Randomized, Superiority Study Study Product: VerTouchTM   CONFIDENTIAL This document is confidential and the property of the IntuiTap Medical, Inc.    

IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910668] this clinical study in accordance with the design and specific provisions of this protocol. Modifications to the study are acceptable only with an approved protocol amendment. I agree to obtain approval from the IRB and/or regulatory bodies of competent jurisdiction, for the protocol and informed consent before initiating the study, to obtain consent from subjects prior to their enrollment in the study, to collect and record data as required by [CONTACT_570123], to prepare adverse event and study reports as required by [CONTACT_570124].   ________________________________________________ _________________ [Print Name/Title of Principal Investigator]    Date   As a Sub-Investigator, I agree to conduct this clinical study in accordance with the design and specific provisions of this protocol. Modifications to the study are acceptable only with an approved protocol amendment. I agree to obtain approval from the IRB and/or regulatory bodies of competent jurisdiction, for the protocol and informed consent before initiating the study, to obtain consent from subjects prior to their enrollment in the study, to collect and record data as required by [CONTACT_570123], to prepare adverse event and study reports as required by [CONTACT_570124].  ________________________________________________ _________________ [Print Name/Title of Sub- Investigator]     Date [Print Location if multi-site protocol]   ________________________________________________ _________________ [Print Name/Title of Sub- Investigator]     Date [Print Location if multi-site protocol] [Add additional sheets as necessary]  
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 3 Version History Version # Approval Date Significant Changes from Previous Version Version1 26 Aug 2020 Original Protocol Version Version 2 25 Nov 2020 Incorporate changes based on FDA pre-submission feedback          
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910669] Information ............................................................................... 12 1.2 Key Study Personnel ............................................................................................ 12 1.2.1 Clinical Coordinator ....................................................................................... 12 1.2.2 Clinical Study Monitor .................................................................................. 12 1.2.3 Medical Monitor ............................................................................................ 12 1.2.4 Statistician ...................................................................................................... 12 2 Introduction / Background and Rationale ................................................................... [ADDRESS_910670] Characteristics .......................................................................... 19 3.10 Intended Use ....................................................................................................... 20 4 Device Accountability ................................................................................................ 20 4.1 Device Receipt ..................................................................................................... 20 4.2 Device Storage ..................................................................................................... 20 4.3 Device Dispensing ................................................................................................ 20 4.4 Device Disposition ............................................................................................... 21 4.5 Return or Destruction of Unused Devices ............................................................ 21 5 Study Objectives ......................................................................................................... 21 6 Study Design ............................................................................................................... 21 6.1 Overview of Study Design ................................................................................... 21 6.2 Anticipated Duration of the Clinical Investigation .............................................. 23 6.3 Evaluation Criteria / Effectiveness and Safety ..................................................... 23 6.3.1 Primary Clinical Endpoint ............................................................................. 23 6.3.2 Secondary Clinical Endpoint(s) ..................................................................... 23 6.3.3 Tertiary Endpoints ......................................................................................... 24 6.3.4 Safety Endpoints ............................................................................................ 24 6.3.5 Exploratory Endpoints ................................................................................... 24 6.4 Study Population .................................................................................................. 25 6.4.1 Sample Size .................................................................................................... 25 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910671] Screening ........................................................................................... 26 6.4.4 Prior and Concomitant Medications .............................................................. 26 6.4.5 Inclusion Criteria ........................................................................................... 26 6.4.6 Exclusion Criteria .......................................................................................... 27 6.4.7 Exit / Discontinuation Criteria ....................................................................... 27 7 Study Procedures ........................................................................................................ 27 7.1 Informed Consent ................................................................................................. 27 7.2 Vulnerable Populations ........................................................................................ 28 7.3 Randomization Scheme ........................................................................................ 28 7.4 Clinical Procedures ............................................................................................... 28 7.4.1 Visit 1 ............................................................................................................. 28 7.4.2 Visit 2 ............................................................................................................. 31 7.5 Follow-Up Procedures and Therapy Transitions .................................................. 32 7.6 Study Timetable / Schedule of Events ................................................................. [ADDRESS_910672] Population(s) for Analysis ....................................................................... 33 8.2 Statistical Methods ............................................................................................... 33 8.2.1 Adjustments for Multiplicity .......................................................................... 34 8.2.2 Primary Effectiveness Analysis ..................................................................... 35 8.2.3 Additional Analyses ....................................................................................... 37 8.2.4 Safety Analyses .............................................................................................. 37 9 Safety and Adverse Events ......................................................................................... 37 9.1 Definitions ............................................................................................................ 37 9.2 Safety Monitoring Plan ........................................................................................ 40 9.2.1 Anticipated Risks / Risk Mitigation ............................................................... 40 9.2.2 Medical Monitoring for Participant Safety .................................................... 43 9.3 Anticipated Adverse Events ................................................................................. 44 9.4 Adverse Event Reporting ..................................................................................... 45 9.4.1 Adverse Events .............................................................................................. 45 9.4.2 Serious Adverse Events ................................................................................. 46 9.4.3 Unanticipated Adverse Device Effects (UADE) ........................................... [ADDRESS_910673] Keepi[INVESTIGATOR_007] ......................................................................... 48 11.1 Confidentiality .................................................................................................... 48 11.2 Source Documents .............................................................................................. 48 11.3 Case Report Forms ............................................................................................. 49 11.4 Clinical Reports .................................................................................................. 49 11.5 Records Retention .............................................................................................. 49 12 Study Monitoring, Auditing, and Inspecting ............................................................ 49 12.1 Study Monitoring Plan ....................................................................................... 50 12.2 Auditing and Inspection ..................................................................................... 50 13 Administrative Study Information ............................................................................ 50 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 6 13.1 Technical Support ............................................................................................... 50 13.2 Pre-Study Site Qualification ............................................................................... 51 13.3 Protocol Amendments After Study Initiation ..................................................... 51 13.4 Materials / Services Provided by [CONTACT_673816] ................. [ADDRESS_910674] Discomfort During Landmarking .......................................................... 56 18.2 Provider Confidence ........................................................................................... 56      
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 7 Study Synopsis Title An Open-Label, Parallel, Randomized Study to Evaluate the Performance of Needle Placements for Diagnostic and Therapeutic Neuraxial Procedures, Using a Handheld Tactile Imaging-based Method Versus Palpation Short Title Study to Evaluate the Performance of Needle Placements for Diagnostic and Therapeutic Neuraxial Procedures Protocol Numbers INT-001 Study Sponsor IntuiTap Medical, Inc. Study Classification FDA has determined that the study may proceed under the NSR provisions of the IDE regulation Study Design An open-label, parallel, randomized study design Study Duration Study duration is anticipated to be approximately 4 months Study Center(s) Approximately 3 sites in the [LOCATION_002] Objectives The primary objective of this study is to establish the superiority of VerTouch versus the conventional palpation technique for the number of insertion attempts required in diagnostic and therapeutic neuraxial procedures. Number of Subjects It is expected that approximately 120 subjects will be screened to meet a target enrollment goal of 96 subjects. Main Inclusion / Exclusion Criteria Inclusion Criteria 1. Males and females aged 18 years and above, inclusive  2. Subjects scheduled for one of the following procedures: • Diagnostic LP (collection of CSF and/or measurement of ICP to diagnose hemorrhaging or neurological infections) • Therapeutic LP (intrathecal injection of therapeutic agents; drainage of CSF to treat pseudotumor cerebri) • Planned orthopedic or obstetric procedure, such as labor/induction, cesarean section, 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 8 hysterectomy, or total hip/knee replacement, with neuraxial anesthesia (injection of anesthetic into spi[INVESTIGATOR_216938]/or epi[INVESTIGATOR_673779])  • Epi[INVESTIGATOR_122501] (use of autologous blood to close holes in the dura mater and relieve PDPH) 3. Subjects having a BMI ≤42kg/m2 Exclusion Criteria 1. Patient does not provide informed consent 2. Skin or soft tissue infection near the puncture site 3. Allergy to local anesthetic 4. Uncorrected coagulopathy 5. Acute spi[INVESTIGATOR_25666] 6. History of lumbar spi[INVESTIGATOR_61691] 7. Prior known failed neuraxial anesthesia 8. Diagnosed scoliosis, thoracic kyphosis, lumbar lordosis, scleroderma, or ankylosing spondylitis, or lumbar spi[INVESTIGATOR_16078] 9. Incarcerated subjects  Study Device VerTouchTM Duration of Device Exposure < 2 hours Reference Therapy Conventional palpation technique used for spi[INVESTIGATOR_673780]: The number of insertion attempts (any forward movement of the needle following puncture of the skin) in the study device group as compared to the control group (palpation). Attempts are counted until confirmation of spi[INVESTIGATOR_673781]. Secondary Endpoints: 1. Incidence of first-insertion success (a case that does not require any reinsertions, but can include any number of redirections) 2. Number of redirections (any forward movement of the 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 9 needle in a new direction not preceded by [CONTACT_673817], counted until confirmation of spi[INVESTIGATOR_673781]) 3. Number of passes (any forward movement of the needle, calculated as the sum of insertions and redirections) 4. Incidence of first-pass success (a case that does not require reinsertions or redirections) 5. Subject discomfort during landmarking on a 100mm VAS scale 6. Provider confidence with the identified insertion site on a 1-5 Likert scale 7. Procedure success as confirmed by [CONTACT_6453]-specific methods: • Epi[INVESTIGATOR_24686]: able to achieve a T10 or greater bilateral sensory level change to cold • Spi[INVESTIGATOR_18227]: able to achieve sensory blockade to surgical stimulus at level desired • Diagnostic and therapeutic LP: return of CSF • Blood patch: able to inject homologous blood into epi[INVESTIGATOR_13814] (entry confirmed by [CONTACT_104231]-of-resistance) Tertiary Endpoints: 1. Localization time (time from first touch of draped patient to identification of an insertion site; for VerTouch, this is the time from device placement to movement of the applicator to the identified insertion site) 2. Insertion time (time from retrieval of marker or local anesthetic assembly until no further needle advancements are made) 3. Number of bone contacts 4. Incidence of referral to radiology Safety Endpoints 1. Incidence of post-dural puncture headache (PDPH) 2. Incidence of unintended dural puncture (specific to epi[INVESTIGATOR_24686]) 3. Incidence of paresthesia during needle insertion (specific to neuraxial anesthesia) 4. Incidence of traumatic tap (results in visible blood 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 10 aspi[INVESTIGATOR_1516]) Exploratory Endpoints: 1. Procedure time (from positioning of the patient to removal of the drape from the subject’s back) 2. Incidence of conversion from spi[INVESTIGATOR_673782] (specific to neuraxial anesthesia) Statistical Methods The primary endpoint will be analyzed using a bootstrap approach for the null hypothesis that VerTouch requires more insertions than palpation. A one-sided 0.025 p-value will be considered as the cut-off for statistical significance.     
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910675] ITT  Intent to Treat LA  Local Anesthetic LP  Lumbar Puncture NP  Nurse Practitioner NSR  Non-Significant Risk OTC  Over the Counter PA  Physician’s Assistant PDPH  Post-Dural Puncture Headache PM  Pain Medicine PHI  Protected Health Information PP  Per Protocol SAE  Serious Adverse Event SAP  Statistical Analysis Plan SD  Standard Deviation UADE  Unanticipated Adverse Device Effect  US  [LOCATION_002] VAS  Visual Analog Scale    
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910676], Suite J Houston, TX  [ZIP_CODE] Phone: [PHONE_13984] [EMAIL_12882] 1.[ADDRESS_910677] North Wales, PA [ZIP_CODE] 1.2.3 Medical Monitor ICON Clinical Research [PHONE_9857] (Telephone) 1.2.[ADDRESS_910678] Morrisville, NC [ZIP_CODE] 2 Introduction / Background and Rationale 2.1 Background Neuraxial procedures, in which a needle is inserted into the spi[INVESTIGATOR_673783] a gap in the vertebrae, are performed at a rate of nearly 13 million per year in the US, across a myriad of diagnostic and therapeutic clinical scenarios. Among these are the 800,000 lumbar punctures (LPs) conducted to diagnose subarachnoid 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 13 hemorrhage or neurological infection, or to treat neurological diseases[1]. There are also 3.1 million deliveries of neuraxial anesthesia to reduce pain during obstetric and orthopedic procedures, such as labor/induction, hysterectomy, and total hip/knee replacement[2,3]. Additionally, there are 9 million epi[INVESTIGATOR_158419] (ESIs) for back and leg pain relief[4]. Finally, there are epi[INVESTIGATOR_620846], in which autologous blood is used to close holes in the dura mater and relieve post-dural puncture headache (PDPH). The standard of care involves manual palpation of the patient’s back to detect the spi[INVESTIGATOR_624017] (SPs) and estimate the location of the interspi[INVESTIGATOR_673784][5,6]. While providers are trained to perform these procedures with meticulous precision and attention to detail, this technique remains highly inaccurate, often requiring multiple insertion attempts to properly place the needle[7,8]. These attempts lead to patient pain and complications, such as traumatic taps and PDPHs; unpredictable procedure times; and poor facility throughput[9,10]. The challenge is only exacerbated in patients with high body mass index (BMI), a factor that already accounts for 13.8% of procedure failures, and is only worsening in the US[11,12]. Challenging cases are often referred to radiology for fluoroscopic guidance, at rates greater than 47% in settings such as emergency medicine (EM)[13]. However, fluoroscopy exposes patients and providers to unnecessary radiation, can rarely be used in perioperative settings, and is associated with high costs for overhead, patient transport, and assembly of a radiology team[14-16]. Ultrasound may also be used to help visualize the vertebrae in challenging cases[17]. However, the modality requires significant training on how to interpret its output, and is cumbersome, requiring a gel medium and manipulation of a needle in combination with an unstable probe. VerTouch™ is a novel device that holds promise to reduce the ambiguity associated with the palpation technique, and to overcome the shortcomings of other imaging-based solutions. VerTouch employs scanning-based tactile imaging to detect spi[INVESTIGATOR_673785], analogous to those sensed during palpation[18]. When pressed against the subject’s lower back, the Device’s imaging component detects the differences in hardness surrounding the spi[INVESTIGATOR_624017]. In real-time, data collected by [CONTACT_673818]™, a 2D pressure map on a full-color display, from which the operator can accurately and intuitively identify a suitable insertion site. VerTouch can be used to mark the identified site with a supplied surgical marker, or to inject local anesthetic and place an introducer or spi[INVESTIGATOR_673786] a safe depth at that site. The Device is then removed, and the procedure is completed in the standard manner. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910679] insertion attempt. With the potential to reduce the number of needed insertions, VerTouch may reduce the frustration, pain, and complications associated with these procedures, and standardize the time associated with both the localization and insertion steps. Combined, these potential benefits may translate into lower associated costs of care for factors like bed and boarding time, as well as readmissions and/or further treatment[19-21]. 2.2 Rationale This study is intended to evaluate the use of VerTouch to reduce the number of insertion attempts compared to the conventional manual palpation technique. 3 Device Description VerTouch is a handheld device, which is capable of assembly and use by a single operator, and requires no connection with peripheral systems or software during clinical use[22,23]. VerTouch includes reusable and disposable parts (Figure	1).  
 Figure 1.  Exploded, oblique view of VerTouch subsystems, including the disposable Base and Sleeve, and reusable Monitor. In this figure, ‘needle guide’ broadly references all needle and marker guidance elements, including the Restrictor. 

IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 15 Not shown are the reusable Charging Station, Power Adapter, and PC Connector, none of which are directly used for clinical operation; as well as the Disposable Packaging, which includes a dedicated mini surgical Marker, and a Dock to facilitate sterile assembly of VerTouch components. The reusable Monitor is the subsystem that performs image acquisition, processing, and display of the TactoMap. It comprises a rechargeable battery, and is sold with a charging station to support repeated use. The disposables include a device Base and a Sleeve, both of which are single use, and provided terminally sterilized via ethylene oxide (EtO). The Base allows for placement of the device against the back, and includes the interactive components for scanning-based imaging and needle or marker guidance; while the Sleeve prevents contamination from the Monitor during use. Further description on these components can be found below; please see the Instructions for Use (IFU)[24] for more detail and illustrations. 3.1 Assembly The sterile disposable components, including the Base, the Sleeve, and a dedicated surgical Marker are supplied in a two-part tray. The Tray is wrapped in a Drape, which is used to create a sterile field for the device. The wrapped Tray comes in a sealed Pouch, along with a disposable Dock, which is used to permit sterile electromechanical assembly between the disposable Base and reusable Monitor. The Device powers on upon assembly, after which the sleeve can be slid over the Monitor, forming the protective barrier.  3.2 Workflow Selection VerTouch can be used to support needle insertion via any of three workflows: marking, placement of a 20-22G, 3.5” or 5” needle, or placement of an introducer. With the marking workflow, the device is used to mark an identified insertion site, but local anesthetic (LA) injection and needle insertion occur after device removal. With the introducer and needle placement workflows, LA is injected, and the needle or introducer is placed to a safe depth, through a depth-limiting mechanism (Restrictor) integrated into the device (Figure	2; see Section 9.2.1 for further description).  The remainder of the insertion is then completed after Device removal, which is enabled by a Needle Release Gate (Gate). Prior to beginning the procedure, the user selects their target workflow. If pursuing a marking workflow, the Needle Guide can be removed by [CONTACT_673819], which reveals the larger-diameter Marker Guide, and replaced later, if needed. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 16  Figure 2.  Oblique view of Needle Guide, with Restrictor in 5”-needle position. 3.[ADDRESS_910680], which approximately align with the L4-5 interspi[INVESTIGATOR_608582]. This is performed prior to drapi[INVESTIGATOR_467433], such that the procedure area is exposed and used to guide Device placement. After Device assembly, the user then grips the Handle on the Base with his/her left hand, and places the assembled Device against the patient’s back. Midline indicators on the Device can be used to support alignment with the midline of the spi[INVESTIGATOR_050]. A rubber Bottom Pad on the Base prevents slippage of the Device along the back during use. 3.4 Imaging The Applicator is the primary component that facilitates scanning-based tactile imaging. A calibrated, pi[INVESTIGATOR_673787] (Sensor) is mounted to the patient-contact[CONTACT_673820], which is designed to optimize feature resolution with minimal application of force (Figure	3). 
 Figure 3.  Bottom view of assembled VerTouch, highlighting sensor mounting. 

IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910681] two SPs in the indicated patients. Via an Applicator Button accessible by [CONTACT_28024]’s right hand, the Applicator can be slid along the craniocaudal (y) axis via the Track; and can be pressed along the anteroposterior axis (z), via a spring mechanism that facilitates [ADDRESS_910682] assembly (PCBA) connects the Sensor to downstream electronics and allows for free y- and z-axis movement; an elastomeric (y-lock) strip ensures that the Applicator cannot slide while being pressed. When the user presses the Applicator at a first location, a linear positioning system is used to display the corresponding 2D pressure data at that location within the imaging range on the screen. The user then slides the Applicator to a new location, and repeats the process until the imaging range is complete. A Force Gauge on the screen (not included in Figure	3) indicates the approximate force of each press to help the user apply the same force across presses. Throughout the imaging process, the user observes the outputted pressure data with the goal of identifying a blue region along the midline corresponding to an interspi[INVESTIGATOR_608582]. Navigation Buttons on the left side of the Monitor (not visible in Figure	3) can be used to adjust screen brightness and/or scanning sensitivity during imaging. In the event of any misalignment and/or the lack of an interspi[INVESTIGATOR_608582], the image can be reset via an operator-facing Reset Button on the Monitor, and scanning can be performed at a new location. 3.5 Insertion The Needle Guide is reversibly attached to the top (cranial side) of the Applicator, and its location is presented as a crosshair overlay in the imaging screen. Once an insertion site is identified, the user slides the Applicator until the crosshair aligns with that site. If a marking workflow has been selected, the user places the Marker directly through the exposed Marker Guide. He/she then removes the Device, and injects LA and inserts his/her preferred needle on the mark. For the placement workflows, LA is first injected directly through the Needle Guide. For introducer placement, the user then places the introducer through the Needle Guide. The Gate is then opened, which allows the Device to be removed from the partially placed introducer. Following Device removal, the introducer is fully inserted and the preferred spi[INVESTIGATOR_673788]. The same is done for needle placement; however, to ensure the needle does not exceed a safe depth while the device is in place, the earlier-described Restrictor is used. The Restrictor is pushed over to align with the Needle Guide for placement of a 3.5” needle; and it is further pulled up for placement of a 5” needle (Figure 4). Locking mechanisms ensure the Restrictor locks in both positions.  
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 18  Figure 4.  Side view (cranial) of VerTouch Needle Guide, depi[INVESTIGATOR_673789], and 3.5” and 5” needle, extracted from the IFU[24]. After needle placement, the Gate is opened to allow the device to be pulled away from the introducer or needle. This accomplished by [CONTACT_673821], craniocaudally; and then leftward, mediolaterally (as viewed against the patient’s back). With any workflow, the ability of the system to assist with accurate insertion-site identification has the potential to be associated with a reduction in insertion attempts, although some redirections may still be necessary considering the fixed, perpendicular orientation of the Needle Guide. All Needle and Marker Guide interactions are performed with the right hand, per standard needle insertion training, regardless of handedness. 3.6 Disassembly Upon needle access to the spi[INVESTIGATOR_158470], the user completes his/her procedure per standard protocol. Following the procedure, the Sleeve and Monitor are disconnected from the Base. The Monitor is dropped into the dock, while the remaining components are disposed of with other disposable procedure components. 3.[ADDRESS_910683] to the same connection port on the Monitor. For study use, the Charging Station also has a data transfer port that allows for connection to a PC for transfer of study data that can be referenced when 

IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 19 investigating anomalous findings and/or can be used to establish a database of human TactoMaps for future development. For a given subject, firmware in the Monitor captures pressure data corresponding to the final scan that was used to identify an insertion site. Sampled at a rate of at least 10Hz, these include Sensor readings before and after integration into the full scanning range (referred to as push images and built images, respectively). Also included is header information for each sample, including the current timestamp, sensitivity value, linear position value, and force level. To provide additional information, users can flag the frame at which the Applicator was moved to align the Needle Guide with their identified site by [CONTACT_673822]. Data transfer software is loaded onto on-site study PCs, which allows for upload of these data from the Monitor following each procedure. 3.[ADDRESS_910684] time and date settings, and/or to perform password-protected firmware updates. 3.[ADDRESS_910685] a BMI of ≤42kg/m2 and may be in the seated or lateral decubitus position. The Device is intended for use by [CONTACT_673823]. Table	1 summarizes some such providers, as well as procedure-specific information, such as the VerTouch workflow(s) applicable to each procedure.  Table 1.  Intended Users and Procedures Name [CONTACT_673844](s) Settings Locations Providers Diagnostic LP Needle placement, marking EM Emergency Room EM Physician, PA NE Neurology Suite Neurologist, Neurosurgeon, PA Therapeutic LP Needle placement, marking NE Neurology Suite Neurologist, Neurosurgeon, PA Neuraxial Anesthesia Marking, introducer placement AN Operating Room Anesthesiologist, CRNA Blood Patch Marking AN Operating Room Anesthesiologist, CRNA ESI Marking PM PM Suite PM Physician, PA, CRNA AN Operating Room Anesthesiologist, PA, CRNA PA = physician assistant; CRNA = certified registered nurse anesthetist; NE = neurology, AN = anesthesiology (includes obstetric and orthopedic); PM = pain medicine 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910686] either handedness, and be seated or standing during use. MDs may include residents (a type of clinical trainee), fellows, and attendings. Not listed below are nurse practitioners (NPs), who are credentialed to perform neuraxial procedures in some facilities. In some states, anesthesiology assistants (AAs) may also perform these procedures in the anesthesiology setting. 3.10 Intended Use VerTouch has not yet been cleared by [CONTACT_8415], and is intended to aid in the localization of an interspi[INVESTIGATOR_608582], and the placement of a needle at the identified site, for diagnostic and therapeutic spi[INVESTIGATOR_673790], including LPs, neuraxial anesthesia (spi[INVESTIGATOR_361021], epi[INVESTIGATOR_71543], and combined spi[INVESTIGATOR_1304]-epi[INVESTIGATOR_71543]), ESIs, and epi[INVESTIGATOR_673791]. The device includes functionality to guide a marking tool or needle. All investigational devices will have the following label statement:  CAUTION – Investigational Device. Limited by [CONTACT_4496] (or [LOCATION_002]) Law to Investigational Use. 4 Device Accountability 4.1 Device Receipt IntuiTap Medical will ship devices directly to the clinical sites, to the attention of the Investigator or designee at that site. Device receipt and inventory procedures will be determined by [CONTACT_361253]’ standard operating procedures. At a minimum, a device inventory log will record device serial numbers for reusables and disposables, date of receipt, and disposition. At least two sets of reusable VerTouch components will be provided to each clinical setting within each site. 4.2 Device Storage Devices will be stored in secured rooms under ambient conditions, which meet VerTouch storage requirements. Reusable monitors will be stored on VerTouch charging stations as described earlier; disposables will be stored in their sterile packaging. Device access will be controlled by [CONTACT_673824]. 4.3 Device Dispensing For each procedure, disposable units will be dispensed for use by [CONTACT_673825]; paired with one of the reusable monitors available within the clinical setting. Device serial numbers will be recorded on the subject’s case report form. Device records will be reconciled at each monitoring 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910687]. Chicago, IL [ZIP_CODE] 5 Study Objectives The primary objective of this study is to establish the superiority of VerTouch versus the conventional palpation technique for the number of needle insertion attempts required in diagnostic and therapeutic neuraxial procedures.	6 Study Design 6.1 Overview of Study Design After Informed Consent is obtained, subjects will be randomized 1:[ADDRESS_910688] landmarking techniques will be used in both groups to identify the procedure area. For subjects randomized to the tactile-imaging group (T), VerTouch will be used to identify an interspi[INVESTIGATOR_673792] a marker, introducer, or needle. For subjects randomized to the palpation group (P), the palpation-landmarking method will be used. After marker, introducer, or needle placement, the procedure will continue in the usual manner for subjects in both groups (Figure	6).  A designated study observer within each setting will record the time to identify an insertion site; time to place the marker, introducer, or needle; number of insertions, re-directions, and bone contacts (counted until confirmation of spi[INVESTIGATOR_673793] 2.0 / 25 Nov 2020 Page 22 can be assessed); incidence of procedure success; subject’s level of discomfort during landmarking; and provider’s level of confidence with the identified insertion site. Total procedure time, incidence of traumatic taps, and incidence of referrals to radiology or pain management will be recorded in all settings. In anesthesiology, incidences of paresthesia, unintended dural puncture, and conversion from spi[INVESTIGATOR_673794], will be collected for exploratory analysis, where applicable. Any usability issues or device malfunctions observed during the clinical study will also be documented. 
Informed Consent Subject Screening
Demographics and Baseline Data CollectionRandomizationProviders:MDPACRNANPPalpationTactile ImagingAccess Spi[INVESTIGATOR_673795] 5.  Overall Study Design Although spi[INVESTIGATOR_673796], there may be variations in setting, subject, and/or provider characteristics. While early VerTouch testing has not evidenced any corresponding variations in device usability and/or outcomes associated with these variations, the study is designed to capture them. Accordingly, EM, neurology, and anesthesiology settings will be approximately evenly represented in the study, with at least [ADDRESS_910689] to reimbursement, for ESIs performed with palpation or other non-fluoroscopic techniques. However, PM providers will be represented in IntuiTap’s summative usability study, and undergo the same 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 23 anesthesiology training as those clinical study investigators specialized in obstetrics and orthopedics. Additionally, investigators will form a representative sample of typi[INVESTIGATOR_673797], including MDs (residents, fellows, and attendings), PAs, and CRNAs, where applicable. Residents must be in their second post-graduate year and above, having performed at least [ADDRESS_910690] year. To ensure adequate user variability, a single investigator should perform no more than 20% of procedures in his/her setting (corresponding to a minimum of approximately 6 procedures per investigator). Any provider type not included in the study will have been assessed in formative and/or summative human factors testing. 6.2 Anticipated Duration of the Clinical Investigation Study duration is anticipated to be approximately 4 months. 6.3 Evaluation Criteria / Effectiveness and Safety 6.3.1 Primary Clinical Endpoint The number of insertion attempts (any forward movement of the needle following puncture of the skin) in the study device group as compared to the control group (palpation). Attempts are counted until confirmation of spi[INVESTIGATOR_673781]. 6.3.2 Secondary Clinical Endpoint(s) 1. Incidence of first-insertion success (a case that does not require any reinsertions, but can include any number of redirections) 2. Number of redirections (any forward movement of the needle in a new direction not preceded by [CONTACT_673817], counted until confirmation of spi[INVESTIGATOR_673781]) 3. Number of passes (any forward movement of the needle, calculated as the sum of insertions and redirections) 4. Incidence of first-pass success (a case that does not require reinsertions or redirections) 5. Subject discomfort during landmarking on a 100mm VAS (See Section 17.1)  
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 24 6. Provider confidence with the identified insertion site on a 1-5 Likert scale (See Section 17.2) 7. Procedure success as confirmed by [CONTACT_6453]-specific methods: • Epi[INVESTIGATOR_24686]: able to achieve a T10 or greater bilateral sensory level change to cold • Spi[INVESTIGATOR_18227]: able to achieve sensory blockade to surgical stimulus at level desired • Diagnostic and therapeutic LP: return of CSF • Blood patch: able to inject homologous blood into epi[INVESTIGATOR_13814] (entry confirmed by [CONTACT_104231]-of-resistance) 6.3.3 Tertiary Endpoints 1. Localization time (time from first touch of draped patient to identification of an insertion site; for VerTouch, this is the time from device placement to movement of the applicator to the identified insertion site) 2. Insertion time (time from retrieval of marker or LA assembly until no further needle advancements are made) 3. Number of bone contacts (counted until confirmation of spi[INVESTIGATOR_673781]) 4. Incidence of referral to radiology 6.3.[ADDRESS_910691]-dural puncture headache (PDPH) 2. Incidence of unintended dural puncture (specific to epi[INVESTIGATOR_24686]) 3. Incidence of paresthesia during needle insertion (specific to neuraxial anesthesia) 4. Incidence of traumatic tap (results in visible blood aspi[INVESTIGATOR_1516]) 6.3.5 Exploratory Endpoints 1. Procedure time (from positioning of the patient to removal of the drape from the subject’s back)  2. Incidence of conversion from spi[INVESTIGATOR_673782] (specific to neuraxial anesthesia) 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 25 6.4 Study Population Subjects admitted to EM, neurology, or anesthesiology settings that require a neuraxial procedure as part of their management or work up, and that meet inclusion and exclusion criteria will be approached by [CONTACT_673826]. Spi[INVESTIGATOR_673798], through access to the spi[INVESTIGATOR_158470]. Written informed consent will be obtained in person by [CONTACT_673827].  6.4.1 Sample Size It is expected that approximately 120 subjects will be screened to meet a target enrollment goal of 96 subjects (48 in each group) across 3 investigational sites. The superiority hypothesis for the number of insertion attempts with IntuiTap (µ1) and palpation (µ2) is: H0: µ1 ≥ µ2  vs  H1: µ1 < µ2  The sample size was selected based on historical information and previous clinical trial data collected with the VerTouch device. A literature survey identified eight (8) papers where the mean and standard deviation (SD) for insertions for palpation were identified[25-32]. The definitions appear similar to the proposed endpoint. The mean attempts ranged from 1.[ADDRESS_910692] deviations provided an average of mean of 2.3 and SD of 2.8[33]. Based on the spread of individual results, a mean of 2.1 and SD of 1.5 was considered a reference for the power analysis. A sample of 81 attempts was available for the VerTouch device across several iterations of the device. Of the attempts, 90% were successes on the first attempt and the mean number of attempts was 1.[ADDRESS_910693] of log-transformed data. For a sample size of 24 subjects per group, the bootstrap analysis, 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910694] 92% power while a T-test of the observed counts had 89% power.   In addition, an estimate of the secondary endpoint of first attempt success of approximately 50% was obtained in the simulation exercise for palpation. The planned sample size of 48 per group provides 90% power when compared to a first attempt success rate of 81% in the VerTouch group. Hence, the study is also expected to have adequate power for the primary analysis and the secondary endpoint of success on the first insertion. 6.4.[ADDRESS_910695] number. 6.4.4 Prior and Concomitant Medications There are no restrictions on prior or concomitant medications. However, concomitant prescription and over the counter (OTC) pain and anti-anxiety medications must be recorded in the source documentation and in the eCRF. 6.4.[ADDRESS_910696]: 1. Males and females aged 18 years and above, inclusive 2. Subjects scheduled for one of the following procedures: • Diagnostic LP (collection of CSF and/or measurement of ICP to diagnose hemorrhage or neurological infection) • Therapeutic LP (intrathecal injection of therapeutic agents; drainage of CSF to treat pseudotumor cerebri) 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 27 • Planned orthopedic or obstetric procedure, such as labor/induction, cesarean section, hysterectomy, or total hip/knee replacement, with neuraxial anesthesia (injection of anesthetic into spi[INVESTIGATOR_216938]/or epi[INVESTIGATOR_673779])  • Epi[INVESTIGATOR_122501] (use of autologous blood to close holes in the dura mater and relieve PDPH) 3. Subjects having a BMI ≤42kg/m2 6.4.[ADDRESS_910697]:  1. Patient does not provide informed consent 2. Skin or soft tissue infection near the puncture site 3. Allergy to local anesthetic 4. Uncorrected coagulopathy 5. Acute spi[INVESTIGATOR_25666] 6. History of lumbar spi[INVESTIGATOR_61691] 7. Prior known failed neuraxial anesthesia 8. Diagnosed scoliosis, thoracic kyphosis, lumbar lordosis, scleroderma, ankylosing spondylitis, or lumbar spi[INVESTIGATOR_16078] 9. Incarcerated subjects 6.4.7 Exit / Discontinuation Criteria Subjects will exit the study if any of the following conditions exist: 1. Subject voluntarily withdraws from the study. 2. Subject death. 3. Subject acquires any of the listed exclusion criteria. 4. Subject completes the protocol. 5. Subject’s well-being, in the opi[INVESTIGATOR_689], would be compromised by [CONTACT_673828]. 7 Study Procedures 7.1 Informed Consent All prospective subjects for this study will be provided a consent form describing this study and providing sufficient information for subjects to make an informed decision about their participation in this study. The consent form will be submitted 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910698] be kept on-site and by [CONTACT_737]. Subjects who sign an informed consent will be considered enrolled in this study. Subjects who provide consent for participation but do not meet all study eligibility criteria will be considered screen failures. 7.2 Vulnerable Populations As noted above adolescent subjects (18-21 years) will be eligible for participation in this study. Pregnant women will be recruited for the cohort including obstetric procedures, such as labor/induction and cesarean section, and eligible to participate in other cohorts as well.  Other recognized vulnerable populations will not be targeted for recruitment, however individual subjects within vulnerable populations may be enrolled. The Human Subject’s Protections procedures employed in this protocol are sufficient to protect the rights and welfare of any subject within an eligible vulnerable population and no additional measures are necessary. 7.3 Randomization Scheme Qualifying subjects will be randomized 1:1 via a block randomization scheme to either the tactile-imaging group (T) or the palpation group (P) within each setting (e.g. EM, neurology, or anesthesiology). 7.4 Clinical Procedures 7.4.1 Visit 1 Screening  At the screening visit the following activities and information will be collected: • Informed Consent • Physical Examination (height/weight) • Eligibility Determination • Randomization and Subject ID Assignment 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 29 • Demographics (gender, age, race, ethnicity) • Relevant Medical History • Concomitant Medications At Treatment At the time of treatment, the following activities and information will be collected:  • Concomitant Medications • Pain and/or anti-anxiety medication(s) given for the procedure  • Provider level of training (e.g. resident, fellow, attending, PA, CRNA, NP) • Provider number of years of in practice • Provider experience (i.e. number of neuraxial procedures performed in the past 12 months) • Provider specialty (i.e. emergency medicine, neurology, anesthesiology) • Procedure setting (i.e. emergency medicine, neurology, orthopedic anesthesiology, obstetric anesthesiology) • Type of neuraxial procedure (i.e. diagnostic LP, therapeutic LP, spi[INVESTIGATOR_18227], epi[INVESTIGATOR_24686], CSE, blood patch) • Reason for Neuraxial Procedure (if not diagnostic LP or blood patch), such as: o Therapeutic LP: CSF drainage, intrathecal injection, other o Orthopedic procedure: total hip replacement, total knee replacement, other o Obstetric procedure: labor/induction, cesarean section, hysterectomy, tubal ligation, other  The subject will be treated with the device or control, per Figure	6 below (see IFU for more detailed VerTouch steps)[24]. Initial landmarking for vertebral level is performed by [CONTACT_673829] a safe level when placing the drape to expose the procedure area. Listed data will be recorded in source documentation, by a member of the study team designated as an observer, as they become available. The observer will also be responsible for counting needle insertions and redirections. Note that procedure success may be reported at different points within the treatment, depending on when spi[INVESTIGATOR_673799]. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910699]-Treatment After the completion of the procedure, the following activities and information will be collected: • Patient position (seated, lateral decubitus) 

IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 31 • Length, gauge, bevel (cutting, non-cutting), and type (straight, curved) of needle used  • VerTouch workflow followed (N/A (control group), marking, introducer placement, needle placement) • Calculation of number of re-insertions (1 less than insertions) • Incidence of first-insertion success (1 insertion, any number of redirections) • Calculation of number of passes (sum of insertions and redirections) • Incidence of first-pass success (1 pass) • Calculation of localization, insertion, and procedure times (based on start and end times) • Incidence of traumatic tap • Incidence of referral to radiology • Incidence of conversion from spi[INVESTIGATOR_673782] (neuraxial anesthesia only) • Incidence of paresthesia (neuraxial anesthesia only) • Incidence of PDPH • Intensity of PDPH (mild, moderate, severe) • Incidence of unintended dural puncture (epi[INVESTIGATOR_673800]) • Subject Discomfort Assessment • Provider Confidence Assessment • Adverse Event Assessment • Upload of data from VerTouch Post-procedure, the subject will be monitored for adverse events, adverse device effects or other reportable observations to ensure safety, entering relevant data into the eCRF. At the conclusion of the visit, the subject will be released and considered complete. After each procedure, imaging data from VerTouch will be uploaded by [CONTACT_673830] a study portal to support investigation of any anomalous finds and/or establishment of a human image database.  7.4.[ADDRESS_910700] occur at 3 ± [ADDRESS_910701] Study Exit CRF will be completed. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 32 7.5 Follow-Up Procedures and Therapy Transitions Adverse events identified in the study will be followed to resolution. No additional follow-up procedures or therapy transitions are required. 7.6 Study Timetable / Schedule of Events Table 2.  Schedule of Events Assessment Visit [ADDRESS_910702]-Treatment Follow-up Demographics X    Medical History X    Physical Exam (Height & Weight) X    Inclusion/Exclusion Criteria X    Informed Consent X    Randomization X    Concomitant Medications X X  Procedure Completion  X   Discomfort Assessment   X  Provider Satisfaction Assessment   X  PDPH   X Adverse Event Assessment  X X Adverse Device Effect Assessment  X X  7.[ADDRESS_910703]. Sponsor and the site’s IRB must be notified immediately if this occurs. This should be followed with written confirmation that describes the emergency action and outcomes, to Sponsor and per IRB reporting requirements.  Protocol deviations will be reviewed during routine monitoring visits. Investigators will be required to identify preventive and corrective actions to prevent further deviations. An Investigator may be disqualified from the study for repeated and/or egregious protocol deviations. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910704] Population(s) for Analysis The study populations are defined as follows: • Intent-to-treat population (ITT): Consists of all randomized subjects according to their randomized group. • Per-protocol population (PP): Consists of all subjects who received their randomized treatment, did not have an inclusion or exclusion violation, had a procedure success, and did not have a major protocol deviation. The primary analysis and all study results will be analyzed using the ITT population. The primary analysis will be repeated using the PP population. 8.2 Statistical Methods This section describes the planned statistical analyses for this study. A detailed Statistical Analysis Plan (SAP) will be completed and placed on file prior to enrollment. The SAP will contain a comprehensive explanation of the methodology used in the statistical analyses described below. All CRF data will be made available in data listings or in Excel spreadsheets. Data listings will be sorted by [CONTACT_673831], or adverse event onset date. All statistical analyses will be based on the available data. The study results will be reported in summary tables using standard descriptive statistics. Standard numeric descriptive statistics include the n (number of non-missing observations), mean, median, minimum value, and maximum value. Categorical data will be summarized using the counts and percentages based on the non-missing values.  Statistical analyses will be performed to assess the homogeneity of the study populations, evaluate the primary hypothesis, and evaluate the impact of covariates on the performance of the VerTouch device. Standard statistical tests used for 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910705] for categorical variables. For categorical variables with small cell counts (less than 5), Fisher’s exact test will be used. For inferential analyses, unless otherwise indicated, a two-sided p-value of less than or equal to 0.05 will be considered statistically significant. All confidence intervals (CIs) will be two-sided 95% intervals. Note that p-values reported for tertiary and exploratory endpoints will be used for reporting but would not be used in product labeling. 8.2.1 Adjustments for Multiplicity The study has a single primary endpoint needed for the superiority analysis. If that analysis reaches statistical significance, then the following additional hypothesis of the secondary variables will be considered sequentially such that if one analysis is statistically significant, then the next hypothesis can be evaluated to control for the Type I error for these analyses: Additional Hypothesis 1: The null hypothesis that the binary rate of first-attempt success is the same in both groups will be analyzed using a likelihood ratio test (H0: p1 = p2 vs H1: p1 ≠ p2 where p1 is the success rate in VerTouch subjects and p2 is the success rate in control subjects). The results will be considered statistically significant if the two-sided p-value is less than 0.05 and the VerTouch success rate is higher than the control rate). Additional Hypothesis 2: The null hypothesis that the mean number of redirections is the higher in the VerTouch subjects compared to the control group using a T-test with unequal variance assumption (H0: µ1 ≥ µ2 vs H1: µ1 < µ2 where µ1 is the mean in VerTouch subjects and µ2 is the mean in control subjects). The results will be considered statistically significant if the one-sided p-value is less than 0.025. Additional Hypothesis 3: The null hypothesis that the mean number of passes is the higher in the VerTouch subjects compared to the control group using a T-test with unequal variance assumption (H0: µ1 ≥ µ2 vs H1: µ1 < µ2 where µ1 is the mean in VerTouch subjects and µ2 is the mean in control subjects). The results will be considered statistically significant if the one-sided p-value is less than 0.025. Additional Hypothesis 4: The null hypothesis that the binary rate of first-pass success is the same in both groups will be analyzed using a likelihood ratio test (H0: p1 = p2 vs H1: p1 ≠ p2 where p1 is the success rate in VerTouch subjects and p2 is the success rate in control subjects). The results will be 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 35 considered statistically significant if the two-sided p-value is less than 0.05 and the VerTouch success rate is higher than the control rate). Additional Hypothesis 5: The null hypothesis that the mean subject discomfort rated during landmarking from [ADDRESS_910706] with unequal variance assumption (H0: µ1 ≥ µ2 vs H1: µ1 < µ2 where µ1 is the mean in VerTouch subjects and µ2 is the mean in control subjects). The results will be considered statistically significant if the one-sided p-value is less than 0.025. Additional Hypothesis 6: The null hypothesis that the mean provider confidence with the identified insertion site rated [ADDRESS_910707] with unequal variance assumption (H0: µ1 ≤ µ2 vs H1: µ1 > µ2 where µ1 is the mean in VerTouch subjects and µ2 is the mean in control subjects). The results will be considered statistically significant if the one-sided p-value is less than 0.025. Additional Hypothesis 7: The null hypothesis that the binary rate of procedure success is the same in both groups will be analyzed using a likelihood ratio test (H0: p1 = p2 vs H1: p1 ≠ p2 where p1 is the success rate in VerTouch subjects and p2 is the success rate in control subjects). The results will be considered statistically significant if the two-sided p-value is less than 0.05 and the VerTouch success rate is higher than the control rate). 8.2.[ADDRESS_910708] will be performed by a bootstrap analysis resampling the cases in each group. The null hypothesis for the analysis is: H0: µ1 ≥ µ2  vs  H1: µ1 < µ2 Where µ1 is the mean attempts in the VerTouch group and µ2 is the mean for palpation. This hypothesis will be evaluated using a bootstrap analysis with a one-sided 0.[ADDRESS_910709] to indicate statistical significance. The results will be presented for the difference in means and the associated 95% CI; and the ratio of the VerTouch mean divided by [CONTACT_673832] 95% CI. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910710] regardless of success on the final placement attempt.   The following supporting analyses will be performed: • The primary analysis will be performed only for subjects who had a procedure success. • If there are missing data, best- and worst-case imputation analyses will be performed. For the worst-case imputation, the highest observed value will be imputed in the VerTouch group and the lowest value in the palpation group. The best-case analysis reverses the pattern of imputations.  • A Wilcoxon rank-sum test will be used to evaluate the null hypothesis that median attempts are the same in both arms using a two-sided test with a p-value less than or equal to 0.05 considered significant. • Homogeneity of the log-transformed count results will be assessed using an ANOVA with site, treatment, and site-treatment interaction terms. A p-value for the site-treatment interaction of less than or equal to 0.15 will be considered statistically significant for this analysis. The n, mean, and SD of values by [CONTACT_673833]. • The observed attempts will be evaluated through a t-test for unequal variances comparing the difference in the log (insertion attempts) for each group. The difference will be transformed with the exponent function to provide the ratio of the geometric mean attempts and a two-sided 95% CI for the ratio. The following subgroups will be considered in exploratory covariate analyses: • BMI (kg/m2): underweight (<18.5), normal (18.5-24.9), overweight (25-29.9), class 1 obesity (30.0-34.9), class 2-3 obesity (≥35 .0) • Age (years): adolescent (<22), young adult (22-40), middle-aged adult (41-65), older adult (>65) • Provider type: MD, PA, CRNA, AA, NP • Provider specialty: emergency medicine, neurology, anesthesiology • MD level (MDs only): resident, fellow, attending • Provider years in practice: <5, 5-10, >10 • Provider experience (number of neuraxial procedures in past 12 months): 5-25, 26-50, 51-100, >100 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 37 • Neuraxial procedure: diagnostic LP, therapeutic LP, neuraxial anesthesia, blood patch • Medication given for procedure: none, pain, anti-anxiety • Needle type: spi[INVESTIGATOR_1304] 20-22G cutting, spi[INVESTIGATOR_1304] 20-22G non-cutting, spi[INVESTIGATOR_1304] >22G, Tuohy, CSE • VerTouch workflow (VerTouch subjects only): marking, introducer placement, needle placement Subgroup levels will only be considered if there are at least [ADDRESS_910711]. The tertiary, safety, and exploratory incidence endpoints will be evaluated for homogeneity of the rates across the treatment groups using likelihood ratio tests. 8.2.4 Safety Analyses Adverse events will be summarized using the number and percentage of subjects with one or more events and well as the total count of events. Adverse events will be summarized overall, by [CONTACT_673834], seriousness, and severity. Adverse events will only be summarized descriptively. 9 Safety and Adverse Events 9.1 Definitions Adverse Event (AE) An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the course of the study. Intercurrent illnesses or injuries will be regarded as adverse events. Abnormal results of laboratory or diagnostic procedures are considered to be adverse events if the abnormality: • Results in study withdrawal • Is associated with a serious adverse event 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 38 • Is associated with clinical signs or symptoms • Leads to additional treatment or to further diagnostic tests • Is considered by [CONTACT_125943]. Serious Adverse Event (SAE) A serious adverse event (SAE) is any adverse event that is: • Fatal • Life-threatening • Requires or prolongs a hospi[INVESTIGATOR_4408] • Results in persistent or significant disability or incapacity • Necessitates medical or surgical intervention to prevent one of the outcomes listed above (i.e., to preclude permanent impairment of a body function or permanent damage to a body structure) • A congenital anomaly or birth defect Hospi[INVESTIGATOR_673801] (even if less than 24 hours) to a healthcare facility as a result of a precipi[INVESTIGATOR_355818]; to include transfer within the hospi[INVESTIGATOR_427807]. Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_2505], clinical adverse effect (e.g., for a preexisting condition not associated with a new adverse effect or with a worsening of the preexisting condition; or admission for a protocol-specified procedure) is not, in itself, a serious adverse effect. Unanticipated Adverse Device Effect (UADE) An unanticipated adverse device effect is any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan, or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects. Adverse Event Relationships to the Study Device The relationships between adverse events and the study device will be characterized by [CONTACT_500454]. • Unrelated: This category applies to those adverse events which, after careful consideration, are clearly and incontrovertibly due to extraneous causes (disease, environment, etc.) 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 39 • Possibly Related: This category applies to those adverse events for which, after careful medical consideration at the time they are evaluated, a connection with the study device administration appears unlikely but cannot be ruled out with certainty. An adverse experience may be considered possibly related if or when (at least two of the following): o It follows a reasonable temporal sequence from administration of the study device. o It could not readily have been produced by [CONTACT_423]’s clinical state, environmental or toxic factors, or other modes of therapy administered to the subject. o It follows a known pattern of response to the study device. • Probably Related: This category applies to those adverse events which, after careful medical consideration at the time they are evaluated, are believed with a high degree of certainty to be related to the study device. An adverse experience may be considered probably related if or when (at least three of the following): o It follows a reasonable temporal sequence from administration of the study device. o It could not be reasonably explained by [CONTACT_20612]’s clinical state, environmental or toxic factors or other modes of therapy administered to the subject. o It disappears or decreases on cessation or reduction in device exposure. There are important exceptions when an adverse event does not disappear upon discontinuation of the device, yet device-relatedness clearly exists. o It follows a known pattern of response to the study device. • Definitely Related: An adverse event may be considered definitely related if or when all of the following apply: o The event is a known effect of the device, or procedure o The event follows an obvious sequence of time, from the device’s implantation or activation, or procedure, for which the event is directly attributed to the administration, implantation, activation, or procedure. o The event ceases with discontinuation of the device, or procedure (and reoccurs on restarting). Device Malfunction/Failure – Device Specific Events A device specific event (DSE) is any malfunction of the device, related or not to the device, resulting or not in the patient undergoing undesirable or harmful experience, that occurs in relation with the conduct of the study. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910712]. All AEs/SAEs associated with a device failure are by [CONTACT_167713]. 9.[ADDRESS_910713] for subjects enrolled at that site.  9.2.1 Anticipated Risks / Risk Mitigation As discussed, neuraxial procedures have long been associated with concerns of uncertainty and subjectivity. VerTouch is designed to integrate into the existing clinical workflow and environment; and to offer additional information in support of these procedures, with greater objectiveness than palpation, and greater interpretability than ultrasound. IntuiTap has performed risk analyses in accordance with ISO [ZIP_CODE]:2019, IEC [ZIP_CODE]:2015, IEC [ZIP_CODE]:2006, and IEC [ZIP_CODE]-1, from which the following categories of anticipated VerTouch risks have been identified: • Failure to support proper identification of an insertion site (e.g. generates scanning output that is not uniform, aligned, or sufficiently sensitive)  • Failure to support proper needle insertion (e.g. provides marker or needle guidance that is not accurate, precise, or intuitive) • Tissue trauma (e.g. causes needle dragging, or excessive levels of sustained force) • Standard risks associated with electromechanical medical devices (e.g. is not biocompatible, sterile, or electrically safe) 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910714] two categories could be associated with an increase in procedure time and/or an incorrect needle insertion. In nearly all indications, added time would not result in serious harm. If occurring in emergent cases, particularly in labor/delivery where the opportunity to administer anesthesia could be missed, the provider could revert to the manual procedure. In general, the consequence of an incorrect insertion associated with VerTouch would be identical to that with the standard of care. Namely, it would warrant reinsertions and/or redirections, which can be associated with certain adverse events that are possible in any neuraxial procedure, as listed in Section 9.3, most of which are very rare and/or have low prevalence. Among these, more severe harm exists in epi[INVESTIGATOR_673802], where incorrect insertion can result in incorrect administration of a drug or anesthetic. All risks belonging to the above categories will be reduced as far as possible via safety by [CONTACT_8345], protective measures, and information for safety. To mitigate the risk of device failure, design verification will be completed, including bench, usability, and standards testing, prior to study execution. Labeling will be provided to ensure proper use of all VerTouch components. As with the standard of care and the ultrasound alternative, IntuiTap has assessed the potential for risks in the above categories to be exacerbated by [CONTACT_673835]/or patient characteristics. VerTouch formative and early IRB-approved testing, which has included residents (after their internship) through attendings, and non-MDs, has evidenced no significant difference in use errors and/or insertion performance associated with indicators of provider skill, such as provider level of training or experience with neuraxial procedures. However, to protect the direct risk to subjects, all Investigators will receive the same training on the use of the device and on study procedures, and must be approved by [CONTACT_673836]. Training will follow a checklist that aligns with the IFU, and will include hands-on interaction with the Device. With regard to patient characteristics, formative testing has evidenced some challenges associated with using the Device in simulated patients with high BMI and/or in the lateral-decubitus position, but none that significantly impacted insertion performance. To mitigate these, the indications and instructions for use have been refined to ensure safe and effective Device use across indicated patients; and training will include simulated use in representative challenging cases. IntuiTap has also assessed and mitigated potential risks associated with the Device being left in place during needle insertion. For example, with an earlier version of the Device, there was a potential concern that while the 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910715] be removed from the introducer or needle, such that the user has an unobstructed visualization of the insertion site before he/she continues advancing the needle. Section [IP_ADDRESS] details the evolution of the Restrictor. IntuiTap has also identified and mitigated any lower-level contributors to potential concerns about the Device being left in place during insertion. Among these are design specifications (and verification to these specifications) related to the level of stability and visibility when the device is in place; and the tolerance afforded to a needle during placement and Device removal. Importantly, the VerTouch IFU also includes an instruction for the use of standard landmarking techniques (i.e. palpation of the iliac crest) to identify a safe level for the procedure area prior to Device placement. [IP_ADDRESS] Restrictor Discussion In the course of development, IntuiTap found that there are no anatomical structures in the region that are formally acknowledged as critical, and that needle depth has not been identified as an independent risk factor for any theoretical adverse events associated with placement of a spi[INVESTIGATOR_13911] (such as retroperitoneal bleeding, epi[INVESTIGATOR_110116], and nerve root injury, identified in Section 9.3). However, in a conservative approach, IntuiTap designates a safe depth as within the posterior tissue shallower than the spi[INVESTIGATOR_673785], which includes skin, subcutaneous tissue, small blood vessels, and muscle, all of which are routinely pi[INVESTIGATOR_673803], without significant and/or lasting damage[34-36]. The maximum depth is determined based on tissue thickness for the BMI expected with use of particular spi[INVESTIGATOR_243039], calculated using correlation coefficients provided by a study on spi[INVESTIGATOR_673804][37]. Clinical users have expressed a desire for a minimum depth of 2.0cm or, alternatively, 30% of the needle shaft in order to feel that their introducer or needle is secure enough to remain in the tissue during Device removal. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910716] stated that they can determine a safe initial placement depth without the restrictor, based on training and skill in gauging needle depth by [CONTACT_673837], IntuiTap’s intent was to address this safety objective with minimal complexity and impact on existing workflow. To that end, Restrictor configurations were defined for the most commonly used needles for these procedures: introducers (1.25”), and 3.5” and 5” spi[INVESTIGATOR_243039] (the 5” are a rare alternative to the 3.5”; used only in cases of morbid obesity). The design of the existing Needle Guide reduces the penetrable depth of any needle by 2.0cm, which is what is needed to stop an introducer at the secure depth of 1.0cm. With the appropriate Restrictor configurations, the 3.5” and 5” needles can reach depths of 2.0cm and 3.5cm respectively, which fall within the safe and secure range established by [CONTACT_673838]. In the event that a provider opts to use a 5” needle in lower-BMI cases, literature shows that it will still be prevented from reaching the epi[INVESTIGATOR_13814], less conservatively allowing the needle to be placed through interspi[INVESTIGATOR_11599], if BMI exceeds 20kg/m2; likewise for a 3.5” needle in patients with less than 2.0cm subcutaneous tissue[11,38-40]. The Restrictor embodiment shown in Section 3.5 has been successfully tested in bench and usability studies. It is important to note that in this testing no significant difference has been observed in Device performance using the marking versus introducer or needle placement workflows (except where attributed to shortcomings in test methodology), despi[INVESTIGATOR_673805]. 9.2.2 Medical Monitoring for Participant Safety The Principal Investigator [INVESTIGATOR_193311], including careful assessment and appropriate reporting of adverse events as outlined in Section 9.4. Medical monitoring will include a regular assessment of the number and type of serious adverse events.  Medical Monitor:  ICON Clinical Research [PHONE_9857] (Telephone) 	
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910717] been directly tied to insertion depth (if performed at the correct vertebral level, below the cauda equina). It is important to note that the various risk factors associated with nearly all of these complications lead to great variability in reported rates. In particular, the incidence of most adverse events that can be linked to number of insertion attempts is directly correlated with needle characteristics, such as size and shape[8]. Additionally, rare complications have been found to be associated with the presence of spi[INVESTIGATOR_255558], which are study exclusions[34,35].  Adverse events associated with LPs include[41]: • PDPH, 40% (important risk factors include needle size and shape, use of stylet, patient position, number of attempts, and volume of CSF removed; may lead to the need for further treatment, including epi[INVESTIGATOR_122501])[42]  • Cranial neuropathy, 0.4% • Paresthesia (nerve root irritation), 13%[43]  • Low back pain, 35% • Bacterial meningitis, 0.2% • Intracranial bleeding, rare • Traumatic lumbar puncture, up to 72%, with 15.6% reported for cutoff of 400 erythrocytes/µL in the first tube (in laboratory analysis, may lead to false-positive diagnosis of SAH or other cerebral vascular malformations)[43,44]  • Retroperitoneal abscess, rare[45]  • Spi[INVESTIGATOR_626858], rare Adverse events associated with neuraxial anesthesia include the following (rates are mostly reported for epi[INVESTIGATOR_24686]; where not specific to an epi[INVESTIGATOR_13873], rates are higher with spi[INVESTIGATOR_545630]-epi[INVESTIGATOR_24686])[46,47]: • Unintended dural puncture, 1.5% • Post-dural puncture headache, 0.21-1.5%  • Spi[INVESTIGATOR_673806], 0.0002% • High spi[INVESTIGATOR_100122], 0.002% • Paresthesia (transient neurologic injury), 0.018%[9] • Spi[INVESTIGATOR_626858], 0.0002% 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 45 • Hypotension (requiring treatment), 30% • Persistent neurologic injury, 0.0004%[9]  • Permanent neurological injury, 0.001% • Inadequate analgesic effect (failure), 6.3%  • Pruritus, 12% • Backache, 12% • Nerve damage caused by [CONTACT_673839], 0.0006%  • Epi[INVESTIGATOR_115909], 0.003%  • Bacterial meningitis, 0.003%  • Epi[INVESTIGATOR_110116], 0.0006%  • Fetal heart rate abnormalities: 5.5% • Fetal bradycardia: 4.7% 9.[ADDRESS_910718] findings to determine:  1)  if the abnormal test finding should be classified as an adverse effect;  2)  if there is a reasonable possibility that the adverse effect was caused by [CONTACT_343239], if applicable, other study treatment or diagnostic product(s); and  3)  if the adverse effect meets the criteria for a serious adverse effect. If the Investigator’s final determination of causality is “unknown and of questionable relationship to the investigational device or, if applicable, other study treatment or diagnostic product(s)”, the adverse effect will be classified as associated with the use of the investigational device for reporting purposes. If the investigator’s final determination of causality is “unknown but not related to the investigational device or, if applicable, other study treatment or diagnostic product(s)”, this determination and the rationale for the determination will be documented in the respective subject’s case history. 9.4.[ADDRESS_910719] findings, regardless of treatment group, if applicable, or suspected causal relationship to the investigational device or, if applicable, other study treatment or 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910720](s) will be recorded in the subjects’ case histories. For all adverse effects, sufficient information will be pursued and/or obtained so as to permit:  1)  an adequate determination of the outcome of the effect (i.e., whether the effect should be classified as a serious adverse effect) and;  2) an assessment of the casual relationship between the adverse effect and the investigational device or, if applicable, the other study treatment or diagnostic product(s).  Adverse effects or abnormal test findings felt to be associated with the investigational device or, if applicable, other study treatment or diagnostic product(s) will be followed until the effect (or its sequelae) or the abnormal test finding resolves or stabilizes at an acceptable level. Adverse Events that do not qualify as Serious Adverse Events, or as Unanticipated Adverse Device Effects will be reported to the Sponsor at a designated interval determined by [CONTACT_1034]. Adverse Events that do not qualify as Serious Adverse Events, or as Unanticipated Adverse Device Effects will be reported to the IRB with the continuing review progress report.  9.4.[ADDRESS_910721] information for Serious Adverse Event Notification:   ICON Clinical Research  [PHONE_9857] (Telephone)  At the time of the initial report, the following information should be provided: • Study Identifier • Whether study treatment was discontinued • Study Center • Reason the event is classified as serious • Subject Number • Investigator assessment of association between event and study device • Event Description • Date of Onset • Current Status 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910722] be reported to the IRB within 10 working days.  9.4.3 Unanticipated Adverse Device Effects (UADE) Investigators are required to submit a report of a UADE to the Sponsor and the reviewing IRB as soon as possible, but in no event later than [ADDRESS_910723]. 10 Classification as Non-Significant Risk Study The US Food and Drug Administration (FDA) has determined that the study may proceed under the non-significant risk (NSR) provisions of the IDE regulation.  The rationale for the NSR classification of this study is that the investigational Device does not meet the definition of a significant risk (SR) device under 21 CFR 812.3(m), as further described below: • The Device is not an implant, nor does it present a potential for serious risk to the health safety, or welfare of a subject (812.3(m)(1));  • The Device is not purported or represented to be for a use in supporting or sustaining human life, nor does it present a potential for serious risk to the health, safety, or welfare of a subject (812.3(m)(2));  • The Device is not for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health, nor does it present a potential for serious risk to the health, safety, or welfare of a subject (812.3(m)(3)); and • The Device does not otherwise present a potential for serious risk to the health, safety, or welfare of a subject (812.3(m)(4)).  
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910724] of 1996 (HIPAA). Those regulations require a signed subject authorization informing the subject of the following:  • What protected health information (PHI) will be collected from subjects in this study • Who will have access to that information and why • Who will use or disclose that information • The rights of a research subject to revoke their authorization for use of their PHI.  In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject authorization. For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period. 11.[ADDRESS_910725] data, and other information contained in Source Documents. Source Documents are the original records (and certified copi[INVESTIGATOR_63062]); including, but not limited to, hospi[INVESTIGATOR_38109], physician or office charts, physician or nursing notes, subject diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, x-rays, etc. When applicable, information recorded on the CRF shall match the Source Data recorded on the Source Documents. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 49 11.3 Case Report Forms  The study case report form (CRF) is the primary data collection instrument for the study. All data requested on the CRF must be recorded. All missing data must be explained. If a space on the CRF is left blank because the procedure was not done or the question was not asked, enter “N/D”. If the item is not applicable to the individual case, enter “N/A”.  An electronic Case Report Form will be completed for each subject enrolled into the clinical study. All electronic records will be compliant to 21 CFR Part 11. The investigator will review, approve and sign/date each completed CRF; the investigator’s signature [CONTACT_57322]’s responsibility for ensuring that all clinical and laboratory data entered on the CRF are complete, accurate and authentic.  11.4 Clinical Reports An annual progress report will be submitted to the IRB by [CONTACT_673840]. Investigators will submit a final report of the clinical study to the sponsor and reviewing IRB within 3 months of termination or completion of the clinical study or the Investigator’s part of the clinical study.  Sponsors will notify the FDA within 30 working days of the termination or completion of a significant risk clinical study. Sponsors will submit a final report to FDA, all reviewing IRBs and participating Investigators within 6 months of termination or completion. In the case of a non-significant risk study, the Sponsor shall submit a final report to all reviewing IRBs within 6 months after termination or completion. 11.5 Records Retention  The investigator will retain the specified records and reports for a minimum of 6 years, or up to 2 years after the marketing application is approved for the investigational device; or, if a marketing application is not submitted or approved for the investigational device, until [ADDRESS_910726] been discontinued, whichever is longer. The Investigator will provide the Sponsor with written notice no less than 30 days prior to any scheduled destruction of records. 12 Study Monitoring, Auditing, and Inspecting This study will be monitored according to FDA/GCP guidelines. The Investigator will allocate adequate time for such monitoring activities. The Investigator will also ensure that the monitor or other compliance or quality assurance reviewer is given access to all 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 50 study-related documents and study related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and has adequate space to conduct the monitoring visit. 12.[ADDRESS_910727] monitoring visits at study initiation, study completion, and during the study as required. During these visits the monitor/s will review all aspects of the study to ensure that the protocol and applicable regulatory requirements and ISO [ZIP_CODE]:[ADDRESS_910728] sites regularly to ensure continuous oversight of study processes and follow-up on action items. Independent monitoring of the clinical study for clinical protocol compliance will be conducted periodically by [CONTACT_3436]. In consideration of COVID-19 pandemic issues, where possible/feasible, remote source data verification, remote monitoring and remote investigational site closure visits may be employed. 12.2 Auditing and Inspection The investigator will permit study-related monitoring, audits, and inspections by [CONTACT_1201], the sponsor, government regulatory bodies, and institutional compliance and quality assurance groups of all study related documents (e.g. source documents, regulatory documents, data collection instruments, study data, etc.). The investigator will ensure the capability for inspections of applicable study-related facilities (e.g. pharmacy, diagnostic laboratory, etc.). Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_673841]. [ADDRESS_910729] is Geoffrey Hutchins, Director of Engineering. He can be reached at [PHONE_13985] during normal business hours, Central Time. Outside of these hours, a new device can be used until the Sponsor contact [INVESTIGATOR_440759]. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910730] appropriate research experience and infrastructure to ensure adherence to the protocol and enrollment of sufficient numbers of evaluable subjects. The curriculum vitae (CV) of the Investigator will be maintained in the Sponsor files as documentation of previous medical training, and federal databases will be searched to ensure that the Investigator and/or the site are not prohibited from engaging in federally Sponsored clinical research. The Principal Investigator [INVESTIGATOR_290413], agreeing to comply with all applicable government regulations and the requirements of this study. 13.[ADDRESS_910731] be documented as protocol amendments. For studies conducted under an IDE, FDA approval and/or notification may be required in addition to the IRB approval. 13.4 Materials / Services Provided by [CONTACT_673842]: • VerTouch reusable and disposable components • Technical support as defined in Section 12.1 above • A dedicated PC laptop for study data (if necessary) 14 Ethical Considerations This study is to be conducted according to US and international standards of Good Clinical Practice, applicable government regulations (21 CFR 50, 54, 56 and 812) and Institutional research policies and procedures. This protocol and any amendments will be submitted to a properly constituted independent Institutional Review Board (IRB), in agreement with local legal prescriptions, for formal approval of the study conduct. The decision of the IRB concerning the conduct of the study will be made in writing to the investigator and a copy of this decision will be provided to the sponsor before commencement of this study.  
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910732] results and all data derived from the study. 17 References 1. Hall, M.J., De[LOCATION_009]s, C.J., Williams, S.N., Golosinskiy, A., & Schwartzman, A. (2010). National hospi[INVESTIGATOR_447999]: 2007 summary. National Health Statistics Report, 29. 2. Osterman, M.J.K. & Martin, J.A. (2011). Epi[INVESTIGATOR_673807]: 27-state reporting area, 2008. National Vital Statistics Report, 59(5). 3. Orthoworld (2012). Orthopaedic industry annual report: focus on joint replacement. Orthoknow. Retrieved from: https://www.orthoworld.com/index.php/fileproc/index/knowentADJADJorthoknowADJADJ2012ADJADJorthoknow1206LXLXLXpdf 4. Manchikanti, L., Falco, F.J.E., Singh, V., Pampati, V., Parr, A.T., Benyamin, R.M., Hirsch, J.A. (2012). Utilization of Interventional techniques in managing chronic pain in the Medicare population: analysis of growth patterns from 2000 to 2011. Pain Physician, 15(6), E969-E982. 5. Robbins, E., & Hauser, S.L. (2015). Technique of lumbar puncture. In Kasper, D., Fauci, A.S., Hauser, S.L., Longo, D.L., Jameson, J.L., & Loscalzo, J. (Eds.), Harrison’s principles of internal medicine (19th ed). [LOCATION_001], NY: McGraw-Hill. 6. Farley, A., & McLafferty, E. (2008). Lumbar puncture. Nursing standard, 22(22). 46-48. 7. Bhattacharjee, S., & Kauer, G. (2013). A study on the standard of documentation of lumbar puncture in neurology department of a major Irish Teaching Hospi[INVESTIGATOR_673808]. Annals of Indian Academy of Neurology, 16(4), 627-630. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 53 8. Tung, C.E., So, Y.T., & Lansberg, M.G. (2012). Cost comparison between the atraumatic and cutting lumbar-puncture needles. Neurology, 78(2), 109-113. 9. Ruppen, W., Derry, S., McQuay, H., & Moore, A. (2006). Incidence of epi[INVESTIGATOR_110116], infection, and neurologic injury in obstetric patients with epi[INVESTIGATOR_44187]/anesthesia. Anesthesiology, 105(2), 394-399. 10. Cook, T.M., Counsell, D., & Wildsmith, J.A.W. (2009). Major complications of central neuraxial block: report on the Third National Audit Project of the Royal College of Anaesthetists. British Journal of Anaesthesia, 102(2), 179-190. 11. Halpenny, D., O’Sullivan, K., & Burke, J.P., & Torreggiani, W.C. (2013). Does obesity preclude lumbar puncture with a standard spi[INVESTIGATOR_13911]? The use of computed tomography to measure the skin to lumbar subarachnoid space distance in the general hospi[INVESTIGATOR_63840]. European Radiology, 23(11), 3191-3196. 12. Fryar, C.D., Carroll, M.D., & Ogden, C.L. (2016). Prevalence of overweight, obesity, and extreme obesity among adults aged 20 and over: [LOCATION_002], trends 1960-1962 through 2013-2014. NCHS Health E-Stat. Retrieved from: https://www.cdc.gov/nchs/data/hestat/obesity_adult_13_14/obesity_adult_13_14.htm 13. Kroll, H., et al (2015). Trends in lumbar puncture over 2 decades: a dramatic shift to radiology. American Journal of Roentgenology, 204, 15-19. 14. The Joint Commission (2011). Radiation risks in diagnostic imaging. Sentinel Event Alert, 47. Retrieved from: https://www.wvdhhr.org/rtia/pdf/SEA_47[1].pdf 15. Menger, R.P., Peyton, W.A., Hefner, M., Nanda, A, Cuellar, H. (2017). Economic outcomes of the addition of fluoroscopic guidance to the lumbar puncture procedure: a call for standardized training. Journal of Spi[INVESTIGATOR_050], 6(1). 16. Gaskin, D.J., & Richard, P. (2012). The economic costs of pain in the [LOCATION_002]. The Journal of Pain, 13(8), 715-724. 17. Furness, G., Reilly, M.P., & Kuchi, S. (2002). An evaluation of ultrasound imaging for identification of lumbar intervertebral level. Anaesthesia, 57(3), 277-280. 18. Dahiya, R.S., & Valle, M. (2013). Tactile sensing: definitions and classification. In Dahiya, R.S., & Valle, M. (Eds.), Robotic tactile sensing: technologies and system. Dordrecht, Netherlands: Springer. 19. Pi[INVESTIGATOR_1651], J.M., Batt, R.J., Hilton, J.A., & Terwiesch, C. (2010). The financial consequences of lost demand and reducing boarding in hospi[INVESTIGATOR_200321]. Annals of Emergency Medicine, 58(4), 331-340. 20. Nicks, B.A., & Manthey, D.M. (2012). The impact of psychiatric patient boarding in emergency departments. Emergency Medicine International, 2012. 21. Falvo, T., Grove, L., Stachura, R., Vega, D., Stike, R., Schlenker, M., & Zirkin, W. (2007). The opportunity loss of boarding admitted patients in the emergency department. Academic Emergency Medicine, 14(4), 332-337. 22. Moskowitz, N.C., Traver, J., Garcia-Rojas, X., & Ganjeh, Y. (2018). US10004450B2: tactile sensing device for lumbar punctures. USPTO. 23. Moskowitz, N.C., Traver, J., Garcia-Rojas, X., Ganjeh, Y., Cruz, M., Plumb, J.R., Lowe, J.A., & Jones, A.K.G.P (2019). US10383610B2: Tactile sensing and needle guidance device. USPTO. 24. VerTouch™ Instructions for Use, available upon request. 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 54 25. Chin, KJ, Perlas, A, Chan, V, Brown-Shreves, D, Koshkin, A, & Vaishnav, V (2011). Ultrasound imaging facilitates spi[INVESTIGATOR_673809]. Anesthesiology, 115(1), 94-101. 26. Cho, YC, Koo, DH, Oh, SK, Jeong, WJ, Lee, WS, You, YU, & Yoo, IS (2009). Comparison of ultrasound-assisted lumbar punctures with lumbar puncture using palpation of landmarks in aged patients in an emergency center. Journal of Korean Society of Emergency Medicine, 20(3), 304-309. 27. Grau, T, Leipold, RW, Conradi, R, Martin, E, & Motsch, J (2002). Efficacy of ultrasound imaging in obstetric epi[INVESTIGATOR_24686]. Journal of Clinical Anesthesia, 14(1), 169-175. 28. Lee, WS, Jeong, WJ, Yi, HY, Ryu, S, Lee, JW, & Kim, SW (2008). The usefulness of ultrasound-assisted lumbar puncture on adult patients in the emergency center: comparison with classic lumbar puncture. Journal of Korean Society of Emergency Medicine, 19(1), 562. 29. Mofidi, M, Mohammadi, M, Saidi, H, Kianmehr, N, Ghasemi, A, Hafezimoghadam, P, & Rezai, M (2013). Ultrasound guided lumbar puncture in emergency department: time saving and less complications. Journal of Research in Medical Sciences, 18(4), 303-307. 30. Nomura, JT, Leech, SJ, Shenbagamurthi, S, Sierzenski, PR, O'Connor, RE, Bollinger, M, & Gukhool, JA (2007). Journal of Ultrasound Medicine, 26(1), 1341-1348. 31. Peterson, MA, Pi[INVESTIGATOR_673810], D, Heyming, TW, Abele, JA, & Lewis, RJ (2014). Ultrasound for routine lumbar puncture. Academic Emergency Medicine, 21(1), 130-136. 32. Singla, P, Dixon, AJ, Sheeran, JL, Scalzo, D, Mauldin, FW & Tiouririne, M (2019). Feasibility of spi[INVESTIGATOR_673811]: a prospective randomized controlled trial. Journal of Anesthesia & Clinical Research, 10(2). 33. Wan, X., Wang, W., Liu, J, & Tong, T (2014). Estimating the sample mean and standard deviation from the sample size, median, range, and/or interquartile range. BMC Medical Research Methodology, 14(135). Retrieved from: https://bmcmedresmethodol.biomedcentral.com/track/pdf/10.1186/1471-2288-14-135 34. Bruha, R, & Simon, S (1999). Lumbar puncture complicated by [CONTACT_673843]. Am J Medicine, 107. 35. Aveline, C, & Bonnet, F (2004). Delayed retroperitoneal haematoma after failed lumbar plexus block. Br J of Anaesthesia, 93(4). 36. Myers, M, Meyers, L, & Fink, WA (2015). Extensive subarachnoid and epi[INVESTIGATOR_673812]. Am J Emergency Medicine, 33. 37. Kawchuk, GN, et al (2011). Spi[INVESTIGATOR_673813]. Manual Therapy, 16. 38. Ravi, KK, et al (2011). Distance from skin to epi[INVESTIGATOR_13814]: correlation with body mass index (BMI). Journal of Anaesthesiology Clinical Pharmacology, 27. 39. Hoffmann, VLH, et al (1999). Posterior epi[INVESTIGATOR_673814]: safety of the loss of resistance and hanging drop techniques. British Journal of Anaesthesia, 83(5). 
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / 25 Nov 2020 Page 55 40. Westbrook, JL, et al (1993). Study of the anatomy of the extradural region using magnetic resonance imaging. British Journal of Anesthesia, 71. 41. Evans, RW (1998). Complications of lumbar puncture. Neurologic clinics of North America, 16(1). 42. Frank, RL (2008). Lumbar puncture and post-dural puncture headaches: implications for the emergency physician. The Journal of Emergency Medicine, 35(2). 43. Eskey, CJ and Ogilvy, CS (2001). Fluoroscopy-guided lumbar puncture: decreased frequency of traumatic tap and implications for the assessment of CT-negative acute subarachnoid hemorrhage. American Journal of Neuroradiology, 22. 44. Shah, KH, Richard, KM, Nicholas, S, and Edlow, JA (2003). Incidence of traumatic lumbar puncture. Academic Emergency Medicine, 10(2): 151-154. 45. Boon, JM, Abrahams, PH, Meiring, JH, and Welch, T (2004). Lumbar puncture: anatomical review of a clinical skill. Clinical Anatomy, 17(1): 544-553.  46. Huang, C and Macario, A (2002). Economic considerations related to providing adequate pain relief for women in labour. Pharmacoeconomics, 20(5). 47. Silva, M and Halpern, SH (2010). Epi[INVESTIGATOR_673815]: current techniques. Local and Regional Anesthesia, 3.    
IntuiTap Medical                                                                                                                 CONFIDENTIAL  Version 2.0 / [ADDRESS_910733] Possible   18.2 Provider Confidence Provider confidence in the identified insertion site will be assessed using a Likert scale as below. This scale is to be a total of 100 mm from 1 to 5.           1 Not At All Confident 2 Slightly Confident 3 Somewhat Confident 4 Fairly Confident 5 Completely Confident   